Drugmaker Eli Lilly and Co. told investors on Thursday it will handle the revenue drop that comes from patent expirations by developing more new drugs and boosting sales in Japan, its animal health business and emerging markets.
The Indianapolis drug company has a daunting revenue hole to fill. It loses U.S. patent protection for its top seller, the anti-psychotic Zyprexa, in October and then will go through a string of losses the next few years. Here are the key Lilly drugs that will lose patent protection, when it will happen, and their 2010 U.S. sales figures.
_ Zyprexa, October, $2.5 billion.
_ Cymbalta (antidepressant), 2013, $2.77 billion
_ Humalog (insulin), 2013, $1.22 billion
_ Evista (osteoporosis), 2014, $681.8 million
_ Alimta (cancer), 2016, $957.1 million
_ Cialis (erectile dysfunction), 2017, $658.1 million
Source: Eli Lilly and Co. annual report